Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide

SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), today announced positive results from its Phase 2 study of oral, once-daily VTX3232 in patients with Obesity and Cardiovascular Risk Factors. The 175- participant study examined VTX3232 versus placebo, alone or in combination with semaglutide, evaluating safety and tolerability as the primary endpoint, and effects on inflammation (measured by high-sensitivity C-reactive protein or hsCRP) as the secondary endpoint.   

Read more at globenewswire.com